Arkolith/Insider Trading/ZYME/Form 4

Moore Paul Andrew

Chief Scientific OfficerZymeworks Inc. (ZYME) · full profile →Form 4 · filed Jan 5, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$505K
Net Open-Market Flow
-$505K
Transactions
6
4 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 5, 2026Sell(S)11K$25.10$272K40K
Jan 5, 2026Sell(S)9K$25.10$233K31K
Jan 5, 2026Option exercise(M)17K—$041K
Jan 5, 2026Option exercise(M)20K—$051K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 5, 2026Option exercise(M)20K—$020K
Jan 5, 2026Option exercise(M)17K—$00

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-003095) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML